We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Vela Technologies Plc | LSE:VELA | London | Ordinary Share | GB00BYZ9XC29 | ORD 0.01P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.0035 | 17.95% | 0.023 | 289,750,234 | 16:15:11 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.022 | 0.024 | 0.0245 | 0.0195 | 0.0195 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Investment Advice | -378k | 0.0000 | - | 3.25M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:29:03 | O | 2,165,982 | 0.022 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 05/12/2023 | 11:04 | UKREG | Vela Technologies PLC Holding in Company |
| 01/12/2023 | 15:02 | UKREG | Vela Technologies PLC Exercise of Put Option |
| 17/11/2023 | 08:58 | UKREG | Vela Technologies PLC Notice of AGM |
| 28/9/2023 | 18:03 | ALNC |  EARNINGS: Trellus Health loss narrows, in late-stage product talks |
| 28/9/2023 | 06:00 | UKREG | Vela Technologies PLC Final results for the year ended 31 March 2023 |
| 27/9/2023 | 18:43 | ALNC | TRADING UPDATES: Inland Homes appoints administrators; EDX buys Hutano |
| 27/9/2023 | 06:00 | UKREG | Vela Technologies PLC Quarterly Investment Update |
| 21/9/2023 | 10:14 | ALNC | Vela Technologies and Cizzle Biotechnology rise on Conduit listing |
| 21/9/2023 | 08:01 | UKREG | Vela Technologies PLC Update re. Economic Interest in AZD1656 |
| 08/9/2023 | 14:18 | UKREG | Vela Technologies PLC Further update re. Economic Interest in AZD1656 |
Vela Technologies (VELA) Share Charts1 Year Vela Technologies Chart |
|
1 Month Vela Technologies Chart |
Intraday Vela Technologies Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 09/12/2023 | 08:38 | Vela Technologies | 7,979 |
| 04/12/2023 | 07:05 | CDT need to provide commercial updates | 6 |
| 22/10/2021 | 00:55 | Podcast On VELA | 6 |
| 22/10/2021 | 00:55 | Telegram group | 1 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2023-12-08 16:29:04 | 0.02 | 2,165,982 | 476.52 | O |
| 2023-12-08 16:28:40 | 0.02 | 8,303,282 | 1,826.72 | O |
| 2023-12-08 16:17:43 | 0.02 | 2,000,000 | 468.00 | O |
| 2023-12-08 16:17:34 | 0.02 | 3,000,000 | 663.00 | O |
| 2023-12-08 16:14:52 | 0.02 | 4,500,000 | 1,003.50 | O |
| Top Posts |
|---|
Posted at 09/12/2023 08:20 by Vela Technologies Daily Update Vela Technologies Plc is listed in the Investment Advice sector of the London Stock Exchange with ticker VELA. The last closing price for Vela Technologies was 0.02p.Vela Technologies currently has 16,252,335,184 shares in issue. The market capitalisation of Vela Technologies is £3,250,467. This morning VELA shares opened at 0.02p |
Posted at 04/12/2023 19:52 by steadiereddy 27 Sep 2023 07:00RNS Number : 7461N Vela Technologies PLC 27 September 2023 27 September 2023 Vela Technologies plc ("Vela" or "the Company") Quarterly Investment Update The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 30 June 2023. Executive Director, James Normand, commented: "Market valuations of Vela's listed investee companies remain, like so many others in the small- and micro-cap sector, well below the valuations that one would expect to be applied in 'normal' stock market times. The directors of Vela believe, however, that a number of its investee companies have huge potential; and have therefore determined to hold the shares in those companies until the market cycle results in valuations that are more appropriate to their respective trading and prospects. The Board is particularly pleased that the risk taken nearly three years ago in investing in the development of the AZD1656 drug is at the point where a suitable reward can be reaped." |
Posted at 04/12/2023 19:24 by steadiereddy 12 Jun 2023 11:11RNS Number : 4134C Vela Technologies PLC 12 June 2023 12 June 2023 Vela Technologies plc ("Vela" or "the Company") Holding in Company Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, announces that it was notified on 12 June 2023 that Chris Cooke has a beneficial interest in 1,114,306,333 ordinary shares of 0.01 pence each in the Company representing 6.86 per cent. of the Company's issued share capital. |
Posted at 04/12/2023 19:22 by steadiereddy 1 Jul 2022 13:27RNS Number : 0667R Vela Technologies PLC 01 July 2022 1 July 2022 Vela Technologies PLC ("Vela" or "the Company") Holding in Company Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, was informed yesterday by Antony Laiker that, following an acquisition of ordinary shares in the Company on 30 June 2022, he now has a total beneficial interest in 977,799,500 ordinary shares of 0.01 pence each in the Company ("Ordinary Shares"), representing 6.02 per cent. of the Company's issued share capital. Included within the total beneficial interest stated above are 420,000,000 Ordinary Shares held by BIXX Tech Limited, a company of which Antony Laiker is a director and significant shareholder. |
Posted at 04/12/2023 19:21 by steadiereddy 11 Jul 2022 07:00RNS Number : 9300R Vela Technologies PLC 11 July 2022 11 July 2022 Vela Technologies PLC ("Vela" or "the Company") Holding in Company Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, announces that it was notified on 8 July 2022 that Chris Cooke has a beneficial interest in 757,650,662 ordinary shares of 0.01 pence each in the Company representing 4.66 per cent. of the Company's issued share capital. |
Posted at 30/11/2023 13:00 by steadiereddy Also you have to ask the question - why did Conduit offer Vela a better deal than Cizzle for their share of Royalty ?CIZ were offered $10/share fixed price Whereas Vela have been offered a price range of $5-$15 so potentially Vela can have potentially double the shares (at $5). Maybe Vela haven’t exercised the option yet because there may be commercial news soon on AZD1656 for diabetic Covid use which may result in a higher return than the Conduit shares. Commercial discussions can take a long time and might just be the case here ? |
Posted at 22/11/2023 23:34 by steadiereddy It will be if the CDT share price doesn’t recover to $5 for at least 10 days for Vela to exercise the PUT option.The LSE members seem to think Vela can exercise the PUT option already even when the VWAP is under $5. The problem is that there’s no clarity on what the exact rules are for the PUT option and there’s been no comms from Vela either. |
Posted at 15/8/2023 07:05 by tomboyb Vela Technologies PLC Update re. Economic Interest in AZD165615/08/2023 7:00am UK Regulatory (RNS & others) Vela Technologies (LSE:VELA) Intraday Stock Chart Tuesday 15 August 2023 Click Here for more Vela Technologies Charts. TIDMVELA RNS Number : 2903J Vela Technologies PLC 15 August 2023 15 August 2023 Vela Technologies plc ("Vela" or "the Company") Update on Put Option for potential sale of Economic Interest in AZD1656 Further to the Company's announcement on 15 May 2023, the Board of Vela (AIM: VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, notes that Murphy Canyon Acquisition Corp. (NASDAQ: MURF) ("Murphy") has now received a notice of effectiveness from the United States Securities and Exchange Commission ("SEC") which can be found here: hxxps://www.sec.gov/ As such, Murphy has formally notified its current shareholders that a special meeting will be held on 7 September 2023. This meeting presents an opportunity for Murphy shareholders to provide their approval for the transaction. A link to the notice of special meeting and final prospectus can be found here: hxxps://www.sec.gov/ On 20 April 2023, Vela announced that the Company entered into a put option agreement to give the Company the right, but not the obligation ("the Option"), to sell its economic interest in the commercialisation of the Covid-19 application of AZD1656 for a total consideration of GBP4.0 million. The Option was granted by Conduit Pharmaceuticals Limited ("Conduit") and its prospective parent company, Murphy, a Company listed on NASDAQ. On 15 May 2023, Vela announced that Murphy had filed the Form S-4 Registration Statement and preliminary proxy statement with the SEC. As previously announced on 20 April 2023 and 15 May 2023, the Board of Vela is mindful that there can be no guarantee that Vela will be able to exercise the Option, since exercise is dependent on the successful completion of the merger between Conduit and Murphy and the combined entity being listed on the NASDAQ stock exchange. The Company will release further announcements as and when appropriate. |
Posted at 04/11/2021 13:09 by pwhite73 seG - Be rest assured the drop in Vela share price has sod all to do with a new Covid pill. It is Vela forward selling the next placing at ever attractive prices so the directors can maintain executive lifestyles nothing more. |
Posted at 22/9/2021 09:52 by pwhite73 Now 0.070p - 0.075p. The Vela share price is not connected to anything SGS does. Its connected to the sewage pipeline attached to the equity raising mug PI money drainage system. |
Posted at 17/9/2021 11:12 by pwhite73 O_F - I can accept your argument about the drug being beneficial to diabetics or even diabetics with Covid for that matter.That is not my issue or the scam. The scam was investors were invited to purchase shares in Vela as a result of Vela's investment in a drug that was being trialled for diabetics with Covid. No such drug was ever being trialled. The Arcadia trial was about a drug already being trialled AZD1656 and any benefits it might bring to diabetics with Covid. (Gosh is that so hard to understand). The Phase II trial was a resounding success and the Vela share price has collapsed by 40%. What would have happened if the Phase II trial had been a resounding failure. The same result the Vela share price would have still collapsed by 40%. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
